Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Biomarker Diagnostics in Alzheimer’s Disease
share announcement

Biomarker Diagnostics in Alzheimer’s Disease

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 4027

Special Issue Editors

Dr. Charles R. Harrington

E-Mail Website
Guest Editor
TauRx Therapeutics Ltd., 395 King Street, Aberdeen AB24 5RP, UKSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill Road, Aberdeen AB25 2ZP, UK
Interests: Alzheimer’s disease; neurodegeneration; tau protein; tau-based therapeutics; clinical trials
Special Issues, Collections and Topics in MDPI journals
Prof. Claude M. Wischik

E-Mail Website
Guest Editor
TauRx Therapeutics Ltd., 395 King Street, Aberdeen AB24 5RP, UKSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill Road, Aberdeen AB25 2ZP, UK
Interests: Alzheimer’s disease; frontotemporal dementia; clinical trials; tau protein
Special Issues, Collections and Topics in MDPI journals
Dr. Mohammad Arastoo

E-Mail Website
Guest Editor
Scottish Biologics Facility, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill Road, Aberdeen AB25 2ZP, UK
Interests: Alzheimer’s disease; tau protein; antibodies; biomarkers
Dr. Soumya Palliyil

E-Mail Website
Guest Editor
Scottish Biologics Facility, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill Road, Aberdeen AB25 2ZP, UK
Interests: recombinant antibodies; immunodiagnostics; immunotherapeutics; Alzheimer’s disease; tau protein; biomarkers

Special Issue Information

Dear Colleagues,

Alzheimer’s disease (AD) is a chronic and debilitating neurodegenerative disease that is characterized and diagnosed clinically by progressive cognitive decline. It is well established that the pathophysiology of AD remains clinically silent for decades prior to symptomatic decline. Identifying individuals at risk of disease progression could allow for effective intervention whilst the therapeutic window remains open for preservation of quality of life. To this end, establishing biomarkers of AD can be essential in obtaining a specific molecular signature for each disease stage. Equally important is the need to develop improved diagnostic tests to interrogate biological samples for accurate detection of these disease-specific markers at an early stage and differentiate AD from other forms of dementia.

This Special Issue of Cells aims to introduce new concepts which can enhance our current understanding of AD-specific biomarkers and provide a comprehensive update on recent advances in specific techniques/scientific discoveries that can be instrumental in the early diagnosis and monitoring of disease progression. Original articles and comprehensive reviews which cover topics including candidate biomarker identification in Alzheimer’s disease, novel diagnostic methods using easily accessible biofluids, investigation of biochemical changes in the brain through imaging studies, and development of specific tests tracking AD progression are welcome.

Dr. Charles R. Harrington
Prof. Claude M. Wischik
Dr. Mohammad Arastoo
Dr. Soumya Palliyil
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • AD diagnostics
  • early-stage detection
  • beta-amyloid
  • tau fragments
  • blood-based biomarkers
  • CSF-omics
  • immunodiagnostics
  • neuroimaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

16 pages, 3149 KiB  
Systematic Review
Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
by Alex Zabala-Findlay, Lewis K. Penny, Richard A. Lofthouse, Andrew J. Porter, Soumya Palliyil, Charles R. Harrington, Claude M. Wischik and Mohammad Arastoo
Cells 2023, 12(8), 1184; https://doi.org/10.3390/cells12081184 - 18 Apr 2023
Cited by 8 | Viewed by 3299
Abstract
Objectives: With the development of new technologies capable of detecting low concentrations of Alzheimer’s disease (AD) relevant biomarkers, the idea of a blood-based diagnosis of AD is nearing reality. This study aims to consider the evidence of total and phosphorylated tau as blood-based [...] Read more.
Objectives: With the development of new technologies capable of detecting low concentrations of Alzheimer’s disease (AD) relevant biomarkers, the idea of a blood-based diagnosis of AD is nearing reality. This study aims to consider the evidence of total and phosphorylated tau as blood-based biomarkers for mild cognitive impairment (MCI) and AD when compared to healthy controls. Methods: Studies published between 1 January 2012 and 1 May 2021 (Embase and MEDLINE databases) measuring plasma/serum levels of tau in AD, MCI, and control cohorts were screened for eligibility, including quality and bias assessment via a modified QUADAS. The meta-analyses comprised 48 studies assessing total tau (t-tau), tau phosphorylated at threonine 181 (p-tau181), and tau phosphorylated at threonine 217 (p-tau217), comparing the ratio of biomarker concentrations in MCI, AD, and cognitively unimpaired (CU) controls. Results: Plasma/serum p-tau181 (mean effect size, 95% CI, 2.02 (1.76–2.27)) and t-tau (mean effect size, 95% CI, 1.77 (1.49–2.04)) were elevated in AD study participants compared to controls. Plasma/serum p-tau181 (mean effect size, 95% CI, 1.34 (1.20–1.49)) and t-tau (mean effect size, 95% CI, 1.47 (1.26–1.67)) were also elevated with moderate effect size in MCI study participants compared to controls. p-tau217 was also assessed, albeit in a small number of eligible studies, for AD vs. CU (mean effect size, 95% CI, 1.89 (1.86–1.92)) and for MCI vs. CU groups (mean effect size, 95% CI, 4.16 (3.61–4.71)). Conclusions: This paper highlights the growing evidence that blood-based tau biomarkers have early diagnostic utility for Alzheimer’s disease. Registration: PROSPERO No. CRD42020209482. Full article
(This article belongs to the Special Issue Biomarker Diagnostics in Alzheimer’s Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop